Search Within

Matthew David Hellmann

  1. "Epidemiology and Biostatistics"
Formats
  1. Journal Article (45)
  2. Meeting Abstract (27)
  3. Research Letter (1)
Groups
  1. Department of Medicine (73)
  2. Epidemiology and Biostatistics (73)
  3. Solid Tumor Oncology Division (73)
  4. Thoracic Oncology (73)
  5. GSK Faculty (62)
  6. Biostatistics Service (60)

More Groups

People
  1. Charles Rudin (41)
  2. Hira Rizvi (36)
  3. Gregory Riely (32)
  4. Marc Ladanyi (32)
  5. Mark Kris (31)
  6. Ai Ni (26)

More People

Years
  1. 2024 (2)
  2. 2023 (4)
  3. 2022 (11)
  4. 2021 (4)
  5. 2020 (10)
  6. 2019 (9)

More Years

Publications
  1. Journal of Clinical Oncology (16)
  2. Clinical Cancer Research (8)
  3. Journal of Thoracic Oncology (5)
  4. Annals of Oncology (4)
  5. Cancer Cell (4)
  6. JCO Precision Oncology (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (20)
  2. American Association for Cancer Research (13)
  3. Elsevier Inc. (9)
  4. Nature Publishing Group (6)
  5. Oxford University Press (6)
  6. Cell Press (5)

More Publishers

Results (73)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Concurrent mutations in STK11 and KEAP1 is associated with resistance to PD-(L)1 blockade in patients with NSCLC despite high TMB
    Meeting Abstract

    Arbour, K.; Shen, R.; Plodkowski, A.; Rizvi, H.; Ni, A.; Long, N.; Halpenny, D.; Sanchez-Vega, F.; Rudin, C.; Riely, G.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Clinical and molecular characteristics of EGFR mutant lung cancers with concurrent TP53 and RB1 mutations
    Meeting Abstract

    Offin, M.; Tenet, M.; Shen, R.; Rekhtman, N.; Rizvi, H.; Hellmann, M.; Arcila, M.; Ladanyi, M.; Rudin, C.; Kris, M.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
    Journal Article

    Sabari, J. K.; Leonardi, G. C.; Shu, C. A.; Umeton, R.; Montecalvo, J.; Ni, A.; Chen, R.; Dienstag, J.; Mrad, C.; Bergagnini, I.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non–small-cell lung cancer
    Journal Article

    Arbour, K. C.; Mezquita, L.; Long, N.; Rizvi, H.; Auclin, E.; Ni, A.; Martínez-Bernal, G.; Ferrara, R.; Lai, W. V.; Hendriks, L. E. L.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC
    Journal Article

    Santini, F. C.; Rizvi, H.; Plodkowski, A. J.; Ni, A.; Lacouture, M. E.; Gambarin-Gelwan, M.; Wilkins, O.; Panora, E.; Halpenny, D. F.; Long, N. M.; more...
    Cancer Immunology Research (2018)

    Fulltext@MSK | Save
  • Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition
    Journal Article

    von Reibnitz, D.; Chaft, J. E.; Wu, A. J.; Samstein, R.; Hellmann, M. D.; Plodkowski, A. J.; Zhang, Z.; Shi, W.; Dick-Godfrey, R.; Panchoo, K. H.; more...
    Advances in Radiation Oncology (2018)

    Fulltext@MSK | Save
  • Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance
    Journal Article

    Yu, H. A.; Suzawa, K.; Jordan, E.; Zehir, A.; Ni, A.; Kim, R.; Kris, M. G.; Hellmann, M. D.; Li, B. T.; Somwar, R.; more...
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • Non-conventional inhibitory CD4(+)Foxp3(−)PD-1(hi) T cells as a biomarker of immune checkpoint blockade activity
    Journal Article

    Zappasodi, R.; Budhu, S.; Hellmann, M. D.; Postow, M. A.; Senbabaoglu, Y.; Manne, S.; Gasmi, B.; Liu, C.; Zhong, H.; Li, Y.; more...
    Cancer Cell (2018)

    Fulltext@MSK | Save
  • Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer
    Journal Article

    Hellmann, M. D.; Nathanson, T.; Rizvi, H.; Creelan, B. C.; Sanchez-Vega, F.; Ahuja, A.; Ni, A.; Novik, J. B.; Mangarin, L. M. B.; Abu-Akeel, M.; more...
    Cancer Cell (2018)

    Fulltext@MSK | Save
  • Histologic features predictive of response to PD-1 blockade in patients with non small cell lung carcinoma (NSCLC)
    Meeting Abstract

    Alex, D.; Travis, W.; Rekhtman, N.; Buonocore, D.; Ni, A.; Rizvi, H.; Hellmann, M.; Sauter, J. L.
    Modern Pathology (2018)

    Fulltext@MSK | Save